Clinical trial
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With…
NCT00463814 · AstraZeneca, Industry · Active, not recruiting
Key facts
| NCT number | NCT00463814 |
|---|---|
| Title | AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies |
| Official title | A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies |
| Lead sponsor | AstraZeneca, Industry |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumor, Cancer |
| Intervention type | Drug |
| Interventions | AZD6244 |
| Enrollment | 58 |
| Start date | Mar 8, 2007 |
| Primary completion | Jun 17, 2008 |
| Completion | Dec 31, 2025 |
| First posted | Apr 20, 2007 |
| Last update posted | Nov 13, 2025 |
| Countries | Netherlands, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: